Corbus Pharmaceuticals Holdings, Inc.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.8M | $8.9M | $6.8M | $6.5M | $3.9M | $2.8M |
| Federal Grants | $0 | $0 | $1.3M | $5.2M | $5.0M | $4.1M | $2.1M | $1.2M |
| Development Awards | $0 | $0 | $0 | $2.1M | $1.4M | $2.4M | $1.8M | $1.6M |
| Collaboration Revenue | $0 | $0 | $437.4K | $1.5M | $381.6K | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $31.2M | $16.1M | $36.4M | $98.3M | $89.6M | $48.6M | $26.0M | $15.4M |
| SG&A Expense | $13.9M | $18.7M | $20.4M | $28.5M | $23.6M | $13.0M | $9.0M | $6.5M |
| Operating Income | $-45.1M | $-39.8M | $-56.0M | $-122.8M | $-77.1M | $-56.7M | $-32.6M | $-20.0M |
| Operating Margin | — | — | -3,134.7% | -1,386.9% | -1,132.1% | -867.2% | -829.4% | -716.3% |
| Interest Expense | $3.8M | $3.1M | $2.7M | $1.1M | $0 | — | $3.6K | $3.1K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-44.6M | $-42.3M | $-45.6M | $-111.3M | $-71.5M | $-55.7M | $-32.4M | $-20.0M |
| Net Margin | — | — | -2,555.3% | -1,256.6% | -1,049.2% | -850.8% | -825.8% | -716.7% |
| EPS (Basic) | $-3.44 | $-3.38 | $-3.72 | $-0.47 | $-0.37 | $-0.33 | $-0.22 | $-0.16 |
| EPS (Diluted) | $-3.44 | $-3.38 | $-3.72 | $-0.47 | $-0.37 | $-0.33 | $-0.22 | $-0.16 |
| Shares Outstanding (Basic) | 13.0M | 12.5M | 12.3M | 234.4M | 194.0M | 171.7M | 166.8M | 134.0M |
| Shares Outstanding (Diluted) | 13.0M | 12.5M | 12.3M | 234.4M | 194.0M | 171.7M | 166.8M | 134.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |